{
    "clinical_study": {
        "@rank": "78971", 
        "arm_group": {
            "arm_group_label": "Oral Laxative", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to assess how effective and tolerable the country specific\n      clinical practice guidelines of SLTs are for UK, France and Sweden are.\n\n      The main rationale behind this study is that well controlled comparisons of the various\n      laxatives for the treatment of OIC are lacking.  There is lack of evidence suggesting which\n      laxative or combination of laxatives is optimal for managing OIC."
        }, 
        "brief_title": "A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid Induced Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "detailed_description": {
            "textblock": "The study comprises of nine study visits and the total duration of the study is up to 42-52\n      days Potential subjects, aged 18 years and over, with OIC will be screened for entry into\n      the study at Visit 1 Eligible subjects will attend a 7-day Screening Period (Visit 1).  This\n      will be followed by a 28-day Treatment Period (visits 2 to 8:), made up of four clinic\n      visits scheduled 7 days apart (visits 5(day 7), 6(day 14), 7(day 21), 8(day 28): days 7 to\n      28) and two telephone visits (visits 3 and 4) which will take place during the first week of\n      the Treatment Period.  There will be a 7-day Follow-up Period with a follow-up phone call to\n      conclude the study (Visit 9).\n\n      Study assessment/ evaluation include vital sign measurements, ECG, safety labs, pregnancy\n      test and physical examination assessments, AEs, Investigator and subject questionnaires and\n      subjects daily diaries.\n\n      Subjects will continue to take their prescribed pre-study opioid medication throughout the\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects at least 18 years\n\n          -  Females less than one year post-menopausal must have a negative pregnancy test prior\n             to the first dose of study medication, be non-lactating, and willing to use adequate\n             and highly effective methods of contraception throughout the study. (A highly\n             effective method of birth control is defined as those which result in a low failure\n             rate (i.e. less than 1% per year) when used consistently and correctly e.g.\n             sterilisation, implants, injectables, combined oral contraceptives, some intrauterine\n             devices ((IUDs), hormonal), sexual abstinence or vasectomised partner).\n\n          -  Documented history of malignant or non-malignant pain that requires around-the-clock\n             opioid therapy (WHO step II/III opioid analgesics).\n\n          -  Subjects treated with WHO step II/III opioid analgesics for at least 2 weeks prior to\n             Screening Visit (Visit 1), who will continue with the opioid(s) over the proposed\n             study period.\n\n          -  Subjects meeting the following criteria for OIC:\n\n               -  Subject and Investigator confirm that the Subject's constipation is induced, or\n                  worsened by the Subject's opioid medication (present at Screening)\n\n               -  Subjects with mean BFI score > 30 at Visit 1\n\n               -  Subjects with < 3 complete bowel movements (CBMs) in the week preceding the\n                  Visit 1, based on Subject's retrospective memory in response to Investigator's\n                  question.\n\n          -  Subjects taking at least one laxative on regular basis (i.e. \u22652 intakes per week\n             during the \u22652 weeks prior to screening) for the treatment of OIC.\n\n          -  Subjects must be willing to take SLT.\n\n          -  Subjects taking daily natural dietary fibre supplementation are eligible if they can\n             maintain their diet throughout the study, and in the Investigator's opinion are\n             willing and able to maintain adequate hydration.\n\n          -  Subjects must be willing and able (e.g. mental and physical condition) to participate\n             in all aspects of the study, including use of medication, completion of subjective\n             evaluations, attending scheduled clinic visits, completing telephone contacts, and\n             compliance with protocol requirements as evidenced by providing written, informed\n             consent.\n\n          -  In the Investigator's opinion the Subject's concomitant medication dose will remain\n             stable throughout the study Period (here concomitant medications mean all medications\n             besides opioids (standard and rescue opioid treatment)).\n\n        Exclusion Criteria:\n\n        Medical Conditions:\n\n          -  In the Investigator's opinion any contraindication and precautionary condition for\n             laxative medication(s) used in the study as per the SmPC.\n\n          -  Subjects having any potential non-opioid cause of constipation that might be a major\n             contributor.\n\n          -  Surgery within 2 months prior to the start of the Screening Visit (Visit 1), or\n             planned surgery during the Screening and Treatment periods that may affect GI\n             motility.\n\n          -  Subjects with colostomy or ileostomy.\n\n          -  Hospitalisation expected/planned within the study Period (e.g. planned\n             hospitalisation for the treatment of a pre-existing condition before informed\n             consent) which can affect the outcome measure analysis.\n\n        Treatments/Medications:\n\n        \u2022 Subjects presently taking, or who have taken opioid antagonist(e.g. naloxone, naltrexone\n        and methylnaltrexone) or opioid antagonists containing products (e.g. oxycodone/naloxone,\n        buprenorphine/naloxone, pentazocine/naloxone, tilidine/naloxone)  < 30 days prior to the\n        start of the Screening Period.\n\n          -  Subjects already taking maximum daily dose of country specific SLT (both First and\n             Second Line SLT) on a regular basis (i.e. \u22654 days per week) for the treatment of OIC.\n\n          -  Subjects receiving opioid substitution therapy for opioid addiction (e.g. methadone\n             or buprenorphine).\n\n        Additional Screening Exclusion Criteria for Subjects Suffering from Non-malignant Pain:\n\n        - Subjects who participated in a clinical research study involving a new chemical entity\n        or an experimental drug within 30 days of study entry\n\n        Additional Screening Exclusion Criteria for Subjects Suffering from Malignant Pain:\n\n          -  Subjects who have received a new chemical entity or an experimental drug within 30\n             days of study entry (defined as Visit 1). Concurrent participation in another\n             clinical trial is not permitted except the epidemiological study performed to assess\n             the long-term survival data.\n\n          -  Subjects with an expected life expectancy of < 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957046", 
            "org_study_id": "SLT4501"
        }, 
        "intervention": {
            "arm_group_label": "Oral Laxative", 
            "intervention_name": "Laxative", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Laxatives", 
                "Cathartics", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Opioid induced constipation", 
            "Laxatives"
        ], 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "\u00d6rebro", 
                    "country": "Sweden", 
                    "zip": "703 62"
                }, 
                "name": "Clinical Research Support"
            }, 
            "investigator": {
                "last_name": "Martin Lundvall", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label, Multicentre, Non-randomised, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy for the Reversal of Opioid-induced Constipation in Subjects Suffering From Malignant or Non-malignant Pain That Requires Around-the-clock Opioid Therapy", 
        "overall_contact": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "Maggie c Wilson"
        }, 
        "overall_contact_backup": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "Jill Kiteley"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Recorded in patient diary as and when occurs", 
            "measure": "Change from baseline in soft complete bowel movements", 
            "safety_issue": "No", 
            "time_frame": "Change from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957046"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline (Visit 2 to 8 (Day 1 to 28)) in SCBM - Non Straining", 
                "safety_issue": "No", 
                "time_frame": "change from baseline"
            }, 
            {
                "measure": "Additional laxative use (including enema) in addition to SLT (First Line and Second Line)", 
                "safety_issue": "No", 
                "time_frame": "between visits and overall"
            }, 
            {
                "measure": "Additional procedures (e.g. manual bowel evacuation or surgical procedure) required in addition to SLT", 
                "safety_issue": "No", 
                "time_frame": "between visits and overall"
            }, 
            {
                "measure": "Bowel Function Index (change from baseline to each visit (Day 7, 14, 21 and 28))", 
                "safety_issue": "No", 
                "time_frame": "change from baseline"
            }, 
            {
                "measure": "Compliance with SLT/opioid therapy (premature discontinuation, SLT/opioid dose reduction or completely stopped SLT/opioid therapy).", 
                "safety_issue": "No", 
                "time_frame": "from baseline to end of treatment"
            }, 
            {
                "measure": "SLT/opioid-related AE and dropouts.", 
                "safety_issue": "Yes", 
                "time_frame": "to end of treatment"
            }, 
            {
                "measure": "The modified Subjective Opiate Withdrawal Scale at Day 7 and Day 28", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7 and Day 28"
            }, 
            {
                "measure": "The Clinical Opiate Withdrawal Scale at Day 7 and Day 28", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7 and Day 28"
            }, 
            {
                "measure": "Pain Intensity Scale - \"Average Pain over last 24 Hours\" at each visit (Day 7, 14, 21 and 28)", 
                "safety_issue": "No", 
                "time_frame": "Day 7, 14, 21 and 28"
            }, 
            {
                "measure": "The 36-item Short Form Health Survey (SF-36 v2) at  Day 7 and Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 7 and 28"
            }, 
            {
                "measure": "Clinical Global Impression (CGI) item 1 (severity) Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }, 
            {
                "measure": "Clinical Global Impression (CGI) item 2-4 (condition, therapeutic effect, side effects) Day 7 amd 28", 
                "safety_issue": "No", 
                "time_frame": "Day 7 and 28"
            }, 
            {
                "measure": "The patient global impression of improvement (PGI-I) Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }, 
            {
                "measure": "Healthcare resources used for OIC treatment during the study (between first dose and last dose during the four week treatment period).", 
                "safety_issue": "No", 
                "time_frame": "overall"
            }
        ], 
        "source": "Mundipharma Research GmbH & Co KG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Research GmbH & Co KG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}